Chiasma kicks up summer debt round to $5M
Chiasma Inc., a Newton Center-based biotech, has added to its debt financing round announced last summer, bumping it up from $2 million to $5 million of a planned $6 million, according to federal documents.
Originally, Chiasma had filed documents stating it was looking to cap the debt round at $4 million. The filing with the U.S. Securities and Exchange Commission doesn’t name the seven backers of the extended round individually. Chiasma has its headquarters in Newton Center and its research operations in Jerusalem, Israel.